GU Cancers 2025 | What role will checkpoint inhibitors have in managing penile cancer?
Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, comments on the increasing role of checkpoint inhibitors in penile cancer, citing the upregulation of PD-1 receptors in patients and the growing number of studies evaluating their efficacy in the first-line setting for metastatic disease. More data on checkpoint inhibitors in penile cancer is expected in the future, potentially in combination with radiotherapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the role of checkpoint inhibitors in penile cancer? So I think there is an increasing role of checkpoint inhibitors in penile cancer. And this is based on the background that there is upregulation of PD-1 receptors up to 60% in penile cancer patients. And there are an increasing number of studies, whether it is in single agent or in combination with chemotherapy, which are being evaluated in the first-line setting in the metastatic space...
What is the role of checkpoint inhibitors in penile cancer? So I think there is an increasing role of checkpoint inhibitors in penile cancer. And this is based on the background that there is upregulation of PD-1 receptors up to 60% in penile cancer patients. And there are an increasing number of studies, whether it is in single agent or in combination with chemotherapy, which are being evaluated in the first-line setting in the metastatic space. And potentially they will also be used in combination with radiotherapy and to bring it much earlier in the pathway. So I think in the time to come we’ll see a lot more data on checkpoint inhibitors in penile cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
